Cyclophosphamide treatment

Whole oiganisms and glycoprotein-rich hot-water extracts of C. vulgaris strain CK show not only an antitumor immuno-potentiation [9,10,44] but also a protective effect on bacterial [12,13,15,24,25] and viral [14] infections in murine systems. Hot-water extracts accelerate the recovery of neutrophils and restore protection against infection with K coli in neutropenic states by a cyclophosphamide treatment [13,15], Thus, glycoprotein-rich extracts may not only activate mature leukocytes but also stimulate hematopoietic stem cells in the bone marrow. 

Brodsky RA. High dose cyclophosphamide treatment for autoimmune disorders. Scientific World Journal. 2002 2 1808-1815. 

Spielmann H, Jacob-Mueller U. 1981. Investigations on cyclophosphamide treatment during preimplantation period. 2. In vitro sutides on effects of cyclophosphamide and its metabolites 4-OH-cyclophosphamide, phosphoramide mustard, and acrolein on blastulation of 4- cell and 8-cell mouse embryos and on their development during implantation. Teratology 23 7-13. 

Spielmann H, Habenicht U, Eibs HG, et al. 1981. Investigations on the mechanism of action and on the pharmacokinetics of cyclophosphamide treatment during the preimplantation period in the mouse. Cult Tech 5th Symp Prenatal Dev, 435-445. 

Begin R, Cantin A, Masse S. et al. 1988. Effects of cyclophosphamide treatment in experimental asbestosis. Exp Lung Res 14 823-836. 

Valeri A, Radhakiishiiaii J, Estes D, D Agad V, Kopelmaii R, Peiiiis A, Elis R, Piraiii C, Appel GB (1994) hitraveiious pulse cyclophosphamide treatment of severe lupus iiephrids a prospecdve five-year study. Clin Nephrol 42 71—78. 

Although tumor induction has mostly been documented in patients treated for cancer, long-term cyclophosphamide treatment for non-neoplastic conditions can also increase the incidence of certain neoplasms. Whether this oncogenic effect is a consequence of drug-induced chromosomal aberrations rather than immunosuppression is unclear. An increased incidence of bladder cancers, skin cancers, and myeloproliferative disorders was found in a 20-year follow-up study of 119 patients with rheumatoid arthritis, and a high dose of cyclophosphamide (mean total dose of 80 g) was the main susceptibihty factor (47). 

Renal adenocarcinoma has been reported in a 50-year-old man after 3 years of cyclophosphamide treatment for hepatic sarcoidosis (54). 

Buch RS, Schmidt M, Reichert TE. Akute Nekrose der Zunge unter Epirubicin-Cyclophosphamid-Therapie bei einem invasiv duktalen Mammakatzinom. [Acute tongue necrosis provoked by epirubicin-cyclophosphamide treatment for invasive ductal breast cancer.] Mund Kiefer Gesichtschir 2003 7(3) 175-9. 

Wang CL, Wang F, Bosco JJ. Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus. Lupus 1995 4(1) 11-14. 

Bradley JD, Brandt KD, Katz BP. Infectious complications of cyclophosphamide treatment for vasculitis. Arthritis Rheum 1989 32(l) 45-53. 

Garcia-Porrua C, Gonzalez-Gay MA, Perez de Llano LA, Alvarez-Ferreira J. Fatal interstitial pneumonia due to cytomegalovirus following cyclophosphamide treatment in a patient with systemic lupus erythematosus. Scand J Rheumatol 1998 27(6) 465-6. 

Mauceri HI, Seetharam S, Beckett MA, Schumm LP, Koons A, Gupta VK, Park JO, Manan A, Lee JY, Montag AG, Kufe DW, Weichselbaum RR. Angiostatin potentiates cyclophosphamide treatment of metastatic disease. Cancer Chemother Pharmacol 2002 50 412-A18. 

Acute and fatal cardiovascular collapse developed in two patients when pentostatin was added to h h-dose cyclophosphamide treatment Some recent studies have found the combination to be effective and safe in patients with chronic lymphocytic leukaemia. 

Tc-HYNIC annexin V Allograft rejection, FAS-antibody, cyclophosphamide treatment in tumor bearing rodents Blankenberg et al. (19)... 

Figure 5.9 Cell-transfer experiment transfer of spleen cells from normal High or Low responders into outbred immuno-suppressed recipients. 3 x 10 SE are injected intravenously together with spleen cells. A X rays 950 rad 24 hours before transfer B Cyclophosphamide treatment 6 mg per mouse intraperitoneally 6 hours before transfer.

Positive control of 30-min cyclophosphamide treatment with or without S-9 activation (Aroclor-induced). 

---